Broader Health Technology Assessment (HTA) perspectives capture societal impacts of disease and treatment, including carers ...
Global rare disease policy shifts are reshaping orphan drug development, with major implications for equitable access in the UK, EU and US.
From April 2026, NICE raises its cost-effectiveness threshold to £25k–£35k per QALY. What it means for NHS funding, patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results